Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.

[1]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[2]  T. Welte,et al.  Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends , 2013, PloS one.

[3]  J. Lordan,et al.  Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. , 2013, Respiratory medicine.

[4]  Jeremy S. Brown,et al.  Research priorities in bronchiectasis , 2012, Thorax.

[5]  J. Fothergill,et al.  Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections , 2012, European Respiratory Journal.

[6]  G. Doern,et al.  Antimicrobial Susceptibility Testing , 2011, Journal of Clinical Microbiology.

[7]  S. Holland,et al.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. , 2011, Chest.

[8]  S. Welham,et al.  Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.

[9]  T. S. Wilkinson,et al.  A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. , 2011, American journal of respiratory and critical care medicine.

[10]  C. Steiner,et al.  Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. , 2010, Chest.

[11]  D. Bilton,et al.  British Thoracic Society guideline for non-CFbronchiectasis , 2010, Thorax.

[12]  F. Bastos,et al.  STROBE initiative: guidelines on reporting observational studies. , 2010, Revista de saude publica.

[13]  Cosme Marcelo Furtado Passos da Silva,et al.  Iniciativa STROBE: subsdios para a comunicao de estudos observacionais , 2010 .

[14]  S. Bourke,et al.  Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa , 2010, Thorax.

[15]  M. Metersky.  New treatment options for bronchiectasis , 2010, Therapeutic advances in respiratory disease.

[16]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[17]  D. Bilton,et al.  Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. , 2009, The Journal of antimicrobial chemotherapy.

[18]  A. Hill,et al.  Assessing response to treatment of exacerbations of bronchiectasis in adults , 2008, European Respiratory Journal.

[19]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[20]  M. Steele,et al.  Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  P. King,et al.  Microbiologic follow-up study in adult bronchiectasis. , 2007, Respiratory medicine.

[22]  M. Falagas,et al.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. , 2006, Journal of medical microbiology.

[23]  R. Wilson,et al.  The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis , 2006, European Respiratory Journal.

[24]  G. Viegi,et al.  Coming together: the ATS/ERS consensus on clinical pulmonary function testing , 2005, European Respiratory Journal.

[25]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[26]  G. Oster,et al.  Prevalence and Economic Burden of Bronchiectasis , 2005 .

[27]  D. Bilton,et al.  Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. , 2005, The Journal of antimicrobial chemotherapy.

[28]  J. Chang,et al.  Relationships between High-Resolution Computed Tomography, Lung Function and Bacteriology in Stable Bronchiectasis , 2004, Journal of Korean medical science.

[29]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[30]  M. Keogan,et al.  An investigation into causative factors in patients with bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[31]  K. Yuen,et al.  The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. , 1998, Chest.

[32]  M. Niederman,et al.  Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. , 1998, Chest.

[33]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[34]  P. Jones,et al.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. , 1997, The European respiratory journal.

[35]  M. Denton,et al.  Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic , 1996 .

[36]  M. Woodhead,et al.  Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. , 1996, The European respiratory journal.